Showing results (131-140 of 660) with videos related to
Sort By:
Pageof 66
Nature Cancer|February 18, 2026
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBCNoah F Greenwald, Iris Nederlof, Cameron Sowers, et al.Nature Cancer|November 18, 2024
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancerYang Yang, Michelle L Badura, Patrick C O'Leary, et al.Nature Cancer|May 25, 2026
Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activityAlan Y L Wong, Jacob W Myers, Gyan Prakash, et al.Nature Cancer|June 8, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trialPeter Schmid, Seock-Ah Im, Zbigniew Nowecki, et al.Nature Cancer|April 20, 2026
Heterogeneity and plasticity of cancer-associated fibroblastsSneha Pramod, Hagar Lavon, Ruth Scherz-Shouval, et al.Nature Cancer|April 21, 2026
TMEM87A suppresses ferroptosis and increases cancer immunotherapy resistance by maintaining the Golgi apparatus pH homeostasisJing Li, Yuhan Zhou, Xiong Li, et al.Nature Cancer|May 1, 2026
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 studyNeeltje Steeghs, Carlos Gomez-Roca, Iphigénie Korakis, et al.Nature Cancer|June 4, 2026
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trialGhazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, et al.Nature Cancer|July 20, 2023
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapyTim H H Coorens, Grace Collord, Taryn D Treger, et al.Nature Cancer|August 3, 2023
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinomaAlex Rialdi, Mary Duffy, Alex P Scopton, et al.Pageof 66